8 Oversold Biotech Stocks to Invest In Now
On February 5, J.P. Morgan revealed major themes that are expected to affect healthcare in 2026, emphasizing a resurgence of interest in the biopharma sector.
| No. | Hedge Fund | Shares | Value | Activity | % Port |
|---|---|---|---|---|---|
| 1. | Renaissance Technologies Jim Simons | 313,628 | $220,543 | +100% | 0% |
| 2. | Citadel Investment Group Ken Griffin | 25,587 | $17,993 | -63% | 0% |
| 3. | 24,600 | $17,299 | 0% | ||
| 4. | 10,700 | $7,524 | 0% |
| No. | Name | Shares | Value | % Port |
|---|---|---|---|---|
| 1. | 1,000 | $930 | 0% |